Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

NINDS Recruiting Patients for Phase 2 Idebenone Study

The National Institute of Neurological Disorders and Stroke (NINDS) at NIH is recruting patients for a six month double-blind, placebo-controlled phase 2 clinical trial to determine the safety and efficacy of idebenone administered to patients with Friedreich's Ataxia. NINDS aims to enroll 48 patients composed of children (ages 9-11) and adolescents (ages 12-17) with FA divided evenly among 4 treatment arms (placebo, "low", "intermediate", and "high" dose idebenone).

SHARE

FacebookTwitterLinkedInYoutube
Event F.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator